T2 Biosystems, Inc.
TTOO
$0.1315
-$0.0005-0.38%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 34.85% | -0.61% | -0.82% | -69.38% | -59.97% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 34.85% | -0.61% | -0.82% | -69.38% | -59.97% |
| Cost of Revenue | 4.14% | -30.57% | -6.41% | -30.79% | -48.01% |
| Gross Profit | 4.89% | 39.27% | 8.23% | -44.37% | 43.00% |
| SG&A Expenses | -10.07% | -13.07% | -7.69% | -19.82% | -14.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.36% | -23.23% | -7.00% | -25.95% | -35.47% |
| Operating Income | 8.43% | 26.63% | 7.94% | 0.53% | 29.77% |
| Income Before Tax | 34.41% | -41.22% | 24.66% | -2.39% | 11.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 34.41% | -41.22% | 24.66% | -2.39% | 11.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 34.41% | -41.22% | 24.66% | -2.39% | 11.22% |
| EBIT | 8.43% | 26.63% | 7.94% | 0.53% | 29.77% |
| EBITDA | 6.76% | 25.59% | 6.66% | -1.44% | 30.28% |
| EPS Basic | 83.59% | 91.89% | 97.98% | 98.47% | 98.83% |
| Normalized Basic EPS | 80.40% | 91.89% | 97.90% | 98.45% | 99.00% |
| EPS Diluted | 83.59% | 91.89% | 97.98% | 98.47% | 98.83% |
| Normalized Diluted EPS | 80.40% | 91.89% | 97.90% | 98.45% | 99.00% |
| Average Basic Shares Outstanding | 299.63% | 1,641.88% | 3,637.93% | 6,606.48% | 7,349.75% |
| Average Diluted Shares Outstanding | 299.63% | 1,641.88% | 3,637.93% | 6,606.48% | 7,349.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
